Table 2.
Association between tumour marker expressions and clinicopathological data in 115 colorectal cancers
| Characteristics, n (%) | MC density | PAR-2 expression | Cytoplasmic NHERF1 expression | |||
|---|---|---|---|---|---|---|
| Low | High | Negative | Positive | Negative | Positive | |
| Gender | ||||||
| Male | 26 (39.4) | 40 (60.6) | 31 (47.0) | 35 (53.0) | 32 (48.5) | 34 (51.5) |
| Female | 33 (67.3) | 16 (32.7) | 30 (61.2) | 19 (38.8) | 26 (53.1) | 23 (46.9) |
| P value | 0.004 | NS | NS | |||
| TNM stage | ||||||
| I + II | 17 (45.9) | 20 (54.1) | 23 (62.2) | 14 (37.8) | 28 (75.7) | 9 (24.3) |
| III | 20 (74.1) | 7 (25.9) | 21 (77.8) | 6 (22.2) | 23 (85.2) | 4 (14.8) |
| IV | 22 (43.1) | 29 (56.9) | 17 (33.3) | 34 (66.7) | 7 (13.7) | 44 (86.3) |
| P value | 0.025 | 0.000 | 0.000 | |||
| Differentiation grade | ||||||
| High | 6 (85.7) | 1 (14.3) | 5 (71.4) | 2 (28.6) | 5 (71.4) | 2 (28.6) |
| Moderate | 31 (54.4) | 26 (45.6) | 37 (64.9) | 20 (35.1) | 39 (68.4) | 18 (31.6) |
| Poor | 22 (44.0) | 28 (56.0) | 19 (38.0) | 31 (62.0) | 14 (28.0) | 36 (72.0) |
| P value | 0.051 | 0.005 | 0.000 | |||
| LVI | ||||||
| Negative | 34 (56.7) | 26 (43.3) | 42 (70.0) | 18 (30.0) | 44 (73.3) | 16 (26.7) |
| Positive | 10 (35.7) | 18 (64.3) | 11 (39.3) | 17 (60.7) | 8 (28.6) | 20 (71.4) |
| P value | NS | 0.010 | 0.000 | |||
| EGFR | ||||||
| Negative | 23 (46.9) | 26 (53.1) | 25 (51.0) | 24 (49.0) | 28 (57.1) | 21 (42.9) |
| Positive | 12 (66.7) | 6 (33.3) | 10 (55.6) | 8 (44.4) | 5 (27.8) | 13 (72.2) |
| P value | NS | NS | 0.053 | |||
MC density: density of Tryptase-positive Mast Cell; PAR-2: Proteinase-Activated Receptor 2; NHERF1: Na+/H+ exchanger regulating factor 1; NS: not significant; LVI: lymphovascular invasion.
Significant associations (P < 0.05) are indicated in bold.